New release of Philips EchoNavigator helps interventional teams treat structural heart disease with greater ease and efficiency
16 Maggio 2022 - 10:00AM
New release of Philips EchoNavigator helps interventional teams
treat structural heart disease with greater ease and efficiency
May 16, 2022
- EchoNavigator 4.0 empowers heart teams with greater control of
live fusion imaging plus new anatomical modeling and transseptal
puncture guidance during minimally-invasive procedures
- Seamless integration and communication between Philips
Ultrasound System - EPIQ CVxi - and Philips Image Guided Therapy
System - Azurion - supports efficient fusion-imaging workflow for
minimally-invasive treatment of structural heart disease
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced at EuroPCR (17 - 20 May 2022, Paris, France) the
international launch of EchoNavigator 4.0 [1], the new release of
its advanced image-guided therapy solution for the treatment of
structural heart disease. EchoNavigator 4.0 gives users of Philips’
EPIQ CVXi interventional cardiology ultrasound system greater
control of live fusion-imaging on the company’s Image Guided
Therapy System - Azurion - platform.
By integrating real-time transesophageal echocardiography (TEE),
which places the ultrasound transducer close to the heart, and
X-ray fluoroscopy, EchoNavigator 4.0 helps interventional teams to
decide, guide, treat, and confirm complex structural heart disease
therapy, such as heart valve repair or replacement. The solution
also includes extended anatomical intelligence models, transseptal
puncture guidance to help access the left atrium and mitral valve
from the right atrium, and new 3D live image fusion capabilities,
including Philips’ TrueVue photo-realistic rendering and GlassVue
volumetric imaging modes. It also features automatic selection of
an appropriate set of multiplanar reconstruction planes (sections
taken from the 3D echo heart model), with presets for common views
of the aortic and mitral valves and left atrial appendage.
“The latest EchoNavigator release gives us unique
peri-interventional possibilities by offering a comprehensive set
of automated views based on advanced 3D heart models in combination
with live fusion imaging,” said Dr. Patric Biaggi, Head of Cardiac
Imaging at Heart Clinic Hirslanden in Zurich, Switzerland. “This
allows us to treat our patients with greater confidence and
precision during every stage of the procedure.”
Largely due to lifestyle choices and the aging population,
structural heart disease is now commonplace in older individuals.
In the USA, for example, as many as 1 in 10 people over the age of
75-years are affected by a condition known as mitral regurgitation
[2], which means the mitral valve in their heart does not close
properly, adversely affecting the amount of oxygenated blood that
can be pumped round their body. Worldwide, around 156 million
people are estimated to suffer from the condition [3]. Fortunately,
in many cases treating structural heart disease can now be
performed via image-guided, minimally-invasive, catheter-based
procedures that impose far less trauma than open-heart surgery.
Improved communication and teamworkPhilips
EchoNavigator helps improve communication and teamwork between
echocardiographers and interventionists during image-guided therapy
by automatically fusing together echocardiography ultrasound and
X-ray images, while also enhancing understanding of the
relationship between X-ray and ultrasound in an intuitive way that
helps interventional teams to complete procedures with greater
safety, confidence, and clarity.
“Cardiology teams across the world are facing increasing numbers
of complex structural heart disease cases and are seeking new ways
to deliver effective high-quality care despite staffing shortages,”
said Karim Boussebaa, General Manager of Image Guided Therapy
Systems at Philips. “By helping echocardiographers and
interventionists to work together in even more highly coordinated
ways, this new release of EchoNavigator is an important step
forward in boosting patient throughput, making more efficient use
of time and resources, and achieving positive cardiovascular care
outcomes.”
Greater control for
echocardiographersEchoNavigator 4.0 puts greater control
of imaging in the hands of the echocardiographer via the EPIQ
ultrasound platform’s touch screen, including the ability to fuse
and annotate echocardiography and X-ray fluoroscopy images.
Anatomical features can be identified either manually or
automatically, with anatomical markers and annotations applied to
one modality automatically transposed to the other. Live fusion
images, markers, and annotations are immediately visible to
interventional cardiologists via the Azurion platform’s FlexVision
Pro monitor to help guide catheterization and therapy device
deployment.
Extended automatic modeling and transseptal puncture
guidanceAdditional context and guidance are provided by
EchoNavigator’s automated 3D anatomical modeling capabilities.
These include models for the mitral valve and its leaflets, and
transseptal area models to help identify the optimum zone in the
wall separating the right and left atrium where the septum can be
punctured to catheterize the left atrium and mitral valve. These 3D
modeling capabilities also allow EchoNavigator 4.0 to automatically
select an optimal set of multiplanar reconstruction planes, with
presets for optimally viewing the aortic and mitral valves and left
atrial appendage.
Enhanced fusion imaging with Cardiac TrueVue and TrueVue
Glass renderingEchoNavigator 4.0’s fusion imaging
capabilities have been further enhanced by the ability to fuse live
X-ray fluoroscopy images with live TrueVue and TrueVue Glass
rendered echocardiography images to more easily visualize
positioning and device-tissue interactions. Philips TrueVue 3D
echo rendering improves visualization of anatomical structures and
devices, while TrueVue Glass with Color allows interventionists to
view the location of regurgitant blood flow across a heart
valve.
With its long history of leadership in cardiology innovation,
informed by continuous collaboration with leading clinical
partners, Philips is uniquely positioned to deliver integrated
solutions that span the care pathway to help solve cardiology’s
daily challenges and provide better heart care with greater
efficiency.
[1] Philips EchoNavigator 4.0 is not yet available in all
markets, e.g not available in USA or China.[2] Lloyd-Jones D, Adams
RJ, et al. Heart disease and stroke statistics--2010 update: a
report from the American Heart Association
https://pubmed.ncbi.nlm.nih.gov/20019324/.[3] Dziadzko V, Clavel
MA, Dziadzko M, et al. Outcome and undertreatment of mitral
regurgitation: a community cohort study. Lancet.
2018;391(10124):960-969. doi:10.1016/S0140-6736(18)30473-2
https://pubmed.ncbi.nlm.nih.gov/29536860/.
For further information, please contact:
Joost Maltha Philips Global Press Office Tel:
+31 6 10 55
8116 Email: joost.maltha@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622
698 001E-mail: fabienne.van.der.feer@philips.com
About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people's health and well-being, and enabling better outcomes across
the health continuum – from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company
is a leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2021 sales of EUR 17.2 billion and
employs approximately 79,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips EchoNavigator 4.0
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Mar 2023 a Mar 2024